[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)",
    "summary": "Moderna (NASDAQ:MRNA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ResearchLavina...",
    "url": "https://finnhub.io/api/news?id=dada09ad16e50f0504418d68f6d08aa6ece5cc8216e3814d3b6a45dab5880894",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741708776,
      "headline": "Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)",
      "id": 133139192,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna (NASDAQ:MRNA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ResearchLavina...",
      "url": "https://finnhub.io/api/news?id=dada09ad16e50f0504418d68f6d08aa6ece5cc8216e3814d3b6a45dab5880894"
    }
  },
  {
    "ts": null,
    "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
    "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741683790,
      "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
      "id": 133184494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
      "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327"
    }
  }
]